

File No.- BMSIC/40030/155-2024/10887

दिनांक:-14/03/2024

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना
BMSICL की निविदा संख्या- BMSIC/DRUGS/24-02 से संबंधित प्राप्त ई-निविदाओं के तकनीकी
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/24-02**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 40 (चालीस) ई-निविदा प्राप्त हुई। उक्त 40 (चालीस) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 21/03/2024 के अपराह्न 05:00 बजे तक केवल e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त

(रवीन्द्र कुमार)
महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/24-02						
Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids						
Company Name : - JPEE Drugs Total Number of Pages Submitted in bid documents: -1 to 209						
Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	Yes	18	Yes	—
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	98-101	Yes	As per Bid document clause 3(b) BG Submitted for EMD must be Schedule/Nationalized Bank Payable at Patna But firm has not submitted the same.
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	YES	01	YES	—
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	78	Yes	—
5	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	2	Yes	—
6	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	33-39	Yes	—
7	3.(m)	Copy of Income Tax Return for any three of last four ConsecutiveAssessment years should be submitted (self-attested).	Yes	24-26	Yes	—
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	23	Yes	—
9	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	27-29	Yes	—

Ankharashg
13/3/24

mu ✓

TENDER NO. BMSIC/DRUGS/24-02

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Jpee Drugs. Total Number of Pages Submitted in bid documents:- 209

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	78	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	2	Yes	
3		Minimum three years old valid Manufacturing License of the quoted product.	Yes	52-70	No	For quoted product NIT Sl. No. 10 & 12 product specification is not as per NIT.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	52-70	No	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	40-51	Yes	
6	3.(f)	For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	





Jay 05/03/24

b 05/03/2024

Alash 04/03/2024

B/M 04/03/24

7		FPS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	71-74	Yes	
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	52-70	No	For quoted product NIT Sl. No. 10 & 12 product specification is not as per NIT.
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	40-51	Yes	
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	5	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	7-8	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	6	Yes	

 05/03/24
 05/03/2024
 04/03/2024
 04/03/24

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL asper Annexure-II .	Yes	10-11	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	3-4	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	31-32	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	75-77	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	NA	NA	NA	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provision of "Drugs Price Control Order" (wherever applicable) and the quoted rate should be at least 20% less than its MRP. In extraordinary cases the Managing Director, BMSICL has discretion to take decision. Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII	Yes	82	Yes	

[Signature] 05/03/24

[Signature] 05/03/2024
[Signature] 04/03/24
[Signature] 04/03/24

TENDER NO. BMSIC/DRUGS/24-02

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Jpee Drugs. Total Number of Pages Submitted in bid documents:- 209

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	2	Amitriptyline Hydrochloride	Amitriptyline Hcl Tablet IP 25 mg	25 mg	Each film coated tablet contains: Amitriptyline Hcl IP 25 mg	10x10	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 41)
2	3	Amitriptyline Hydrochloride	Amitriptyline Hcl Tablet IP 10 mg	10 mg	Each film coated tablet contains: Amitriptyline Hcl IP 10 mg	10x10	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 41)
3	5	Calcium carbonate + Vitamin D3	Calcium Tablets	500mg elemental calcium +250 IU D3	Each Uncoated tablet contains: Calcium carbonate IP 1250 mg (Eq. to elemental calcium 500 mg) Vitamin D3 IP 250 IU	10x10	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 42)
4	6	Folic Acid	Folic Acid IP 5 mg	5 mg	Each film coated tablet contains: Folic Acid IP 5 mg	10x10	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 42)
5	7	Ibuprofen	Ibuprofen Tablets	200 mg	Each film coated tablet contains: Ibuprofen IP 200 mg	10x10's	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 42)

105/03/24

05/03/24
04/03/24
04/03/24

6	8	Iron Sucrose	Iron Sucrose Injection	Injection (For IV use) Each ml contain: Ferric Hydroxide in complex with sucrose equivalent to elemental Iron 20 mg	Each ml contains: Ferric Hydroxide complex with sucrose Eq. to elemental Iron 20 mg	5 ml Ampoule	Not mentioned	Injection (For IV Use)	Injection (For IU Use not mentioned)	27.03.2017	12.02.2027	Generic	Submitted (Page no. 42)
7	10	Ondansetron	Ondansetron Orally Disintegration Tablet IP	4 mg	Each uncoated mouth dissolving tablet contains: Ondansetron IP 4 mg (Product specification is not as per NIT)	10x10	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 42)
8	12	Prednisolone	Prednisolone Disperible Tablet 20 mg	20 mg	Each uncoated dispersible tablet contains: Prednisolone IP 20 mg (Product specification is not as per NIT)	10x10	Not mentioned	Tablet	Tablet	27.03.2017	12.02.2027	Generic	Submitted (Page no. 42)
9	15	Sodium Bicarbonate	Sodium Bicarbonate Injection	7.5% w/v	Composition: Sodium Bicarbonate 7.5% w/v	Ampoule	Not mentioned	Injection	Injection	30.08.2017	12.02.2027	Generic	Submitted (Page no. 42)

J. Red
10/03/24

b
05/03/2024
J. Hakim
04/03/2024
B. M.
04/03/24

TENDER NO. BMSIC/DRUGS/24-02

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Jpee Drugs. Total Number of Pages Submitted in bid documents:- 209

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	2	Amitriptyline Hydrochloride	25	18/UA/2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
2	3	Amitriptyline Hydrochloride	25	18/UA/2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
3	5	Calcium carbonate + Vitamin D3	28	19/UA/SC/P-2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
4	6	Folic Acid	28	19/UA/SC/P-2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
5	7	Ibuprofen	25	18/UA/2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
6	8	Iron Sucrose	28	19/UA/SC/P-2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024

Jpee 05/03/24

05/03/24

05/03/24

04/03/24

7	10	Ondansetron	25	18/UA/2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
8	12	Prednisolone	28	19/UA/SC/P-2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024
9	15	Sodium Bicarbonate	28	19/UA/SC/P-2007	NA	NA	13.02.2007	12.02.2027	18.12.2021	16.12.2024

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/155-2024/10095 dt 22.02.2024 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due deligence and care.Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discreprencies are observed for rectification.

Laup
05/03/24

b
05/03/2024

Sharma
04/03/2024

BLM
04/03/24